Skip to Main Content
Contribute Try STAT+ Today

If you follow Alzheimer’s research or have been paying particular attention to the saga over aducanumab, the controversial treatment developed by Biogen, you know that this is a very important week. A panel of experts is convening to decide whether to recommend the Food and Drug Administration approve the drug, which would make it the first new Alzheimer’s treatment in nearly two decades.

But you should also know there is a lot of information to digest — both ahead of the Friday meeting and during it. In the days to come, we’re going to see hundreds of pages of supporting data, debatably legible tea leaves, and diametrically opposed comments from experts around the world. 

Unlock this article by subscribing to STAT+ and enjoy your first 30 days free!


What is it?

STAT+ is STAT's premium subscription service for in-depth biotech, pharma, policy, and life science coverage and analysis. Our award-winning team covers news on Wall Street, policy developments in Washington, early science breakthroughs and clinical trial results, and health care disruption in Silicon Valley and beyond.

What's included?

  • Daily reporting and analysis
  • The most comprehensive industry coverage from a powerhouse team of reporters
  • Subscriber-only newsletters
  • Daily newsletters to brief you on the most important industry news of the day
  • STAT+ Conversations
  • Weekly opportunities to engage with our reporters and leading industry experts in live video conversations
  • Exclusive industry events
  • Premium access to subscriber-only networking events around the country
  • The best reporters in the industry
  • The most trusted and well-connected newsroom in the health care industry
  • And much more
  • Exclusive interviews with industry leaders, profiles, and premium tools, like our CRISPR Trackr.
  • I certainly hope Adam and Damian would be there to cover and report directly all the details preferably throughout the day continuously as befitting theirvincmvedtigstive journalism commitment!

Comments are closed.